secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
CIK:        0000315545
Form:       8-K
Filed at:   2025-01-22T23:59:59+00:00
Accession:  0001493152-25-003193
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Provectus Biopharma approves up to $10M convertible loan financing for drug development
--------------------------------------------------------------------------------

- Board approved 2025 Term Sheet to arrange up to $10M unsecured convertible loan in tranches.
- Loan bears 8% annual interest; principal and interest convertible into Series D-1 Preferred at $2.8620 per share, each convertible into 10 common shares.
- Proceeds to fund drug discovery and development program and general & administrative expenses.
- Company closed 2024 Financing with $1M in convertible promissory notes received as of January 15, 2025.
- Issuance of notes exempt from registration under Section 4(a)(2) or Rule 506 of Regulation D.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/315545/000149315225003193/0001493152-25-003193-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/315545/000149315225003193/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-003193

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer